Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc.

The bulk of cfDNA research is founded upon DNA originating from cancer cells. Circulating tumor DNA (ctDNA) are nucleic biomarkers used to detect or monitor the advancement of cancer over time. These ...

The much-touted arrival of "precision medicine" promises tailored technologies that help individuals and may also reduce health care costs. New research shows how pregnancy screening can meet both of ...

A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of ...

Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney ...

Cell-free DNA (cfDNA) refers to fragments of DNA circulating in the bloodstream that originate from various sources, including dead or dying cells. In recent years, cfDNA has emerged as a promising ...

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA ...

Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication posing significant health risks to both mothers and their newborns. Early detection and treatment of GDM are crucial to ...